

Bryan Wharram

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4852815/publications.pdf>

Version: 2024-02-01

12
papers

819
citations

840776

11
h-index

1125743

13
g-index

13
all docs

13
docs citations

13
times ranked

929
citing authors

#	ARTICLE	IF	CITATIONS
1	A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. <i>Oncotarget</i> , 2016, 7, 10215-10227.	1.8	158
2	Rapid PD-L1 detection in tumors with PET using a highly specific peptide. <i>Biochemical and Biophysical Research Communications</i> , 2017, 483, 258-263.	2.1	132
3	PD-L1 Detection in Tumors Using [⁶⁴ Cu]Atezolizumab with PET. <i>Bioconjugate Chemistry</i> , 2016, 27, 2103-2110.	3.6	128
4	Peptide-Based ⁶⁸ Ga-PET Radiotracer for Imaging PD-L1 Expression in Cancer. <i>Molecular Pharmaceutics</i> , 2018, 15, 3946-3952.	4.6	102
5	Peptide-based PET quantifies target engagement of PD-L1 therapeutics. <i>Journal of Clinical Investigation</i> , 2019, 129, 616-630.	8.2	94
6	Development of [¹⁸ F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide. <i>Molecular Imaging</i> , 2019, 18, 153601211985218.	1.4	52
7	¹⁷⁷ Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2545-2557.	6.4	40
8	A PSMA-targeted theranostic agent for photodynamic therapy. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2017, 167, 111-116.	3.8	39
9	Evaluation of PSMA-Targeted PAMAM Dendrimer Nanoparticles in a Murine Model of Prostate Cancer. <i>Molecular Pharmaceutics</i> , 2019, 16, 2590-2604.	4.6	29
10	Evaluation of ¹¹¹ In-DOTA-5D3, a Surrogate SPECT Imaging Agent for Radioimmunotherapy of Prostate-Specific Membrane Antigen. <i>Journal of Nuclear Medicine</i> , 2019, 60, 400-406.	5.0	19
11	[¹⁸ F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance. <i>Bioconjugate Chemistry</i> , 2016, 27, 1655-1662.	3.6	15
12	CRY ² B2 enhances tumorigenesis through upregulation of nucleolin in triple negative breast cancer. <i>Oncogene</i> , 2021, 40, 5752-5763.	5.9	6